Company profile
Baxter International Inc.
NYSE: BAX · Healthcare · Medical - Instruments & Supplies
#39 of 1,422 Healthcare companies by revenue50th-percentile growth
EA Score
78B+FH 70DQ 95GM 56SS 98
v0.1 · 65/100 weight · provisional
↑ disclosure history, listing tenure · ↓ growth stability, balance-sheet leverage
Methodology →Revenue TTM
$11.3B
Rev growth YoY (TTM)
+5.1%
Net income (FY)
-$957.0M
Employees
37,500
as of 2026-08-06
Market cap
$14.1B
as of 2026-08-06
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$11.2B$11.2B2025
Net income-$957.0M-$957.0M2025
Operating income-$308.0M-$308.0M2025
Total assets$20.1B$20.1B2025
Liabilities$14.0B$14.0B2025
Equity$6.1B$6.1B2025
Revenue trend
FY2023 – FY2025 · USD
FY23
FY23
FY23
FY24
FY24
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Medical Products And Therapies49%
Healthcare Systems and Technologies28%
Pharmaceuticals23%
By geography
UNITED STATES54%
Western Europe, Canada, Japan, Australia and New Zealand33%
EMEA12%
The read
What is Baxter International Inc.’s revenue?
Baxter International Inc. booked $11.2B in FY2025 revenue, growing 5.7% year over year — about the middle of the pack among Healthcare companies we track, at a -8.5% net margin.
Peers · Healthcare
BrightSpring Health Services, Inc. Common Stock69BCommunity Health Systems, Inc.74BVertex Pharmaceuticals Incorporated88AQuest Diagnostics Incorporated88ABausch Health Companies Inc.82B+Intuitive Surgical, Inc.90ANeighbors
Lake →Key facts
CEOAndrew Hider
SectorHealthcare
IndustryMedical - Instruments & Supplies
HeadquartersDeerfield, IL
ExchangeNYSE: BAX
Employees37,500
IPO date1981-10-27
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.